 |
|||||||||
 |
|||||||||
Toronto, Ontario – The Newswire – July 11, 2023 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company“) (TSXV:VPT); (OTC:VPTDF), is pleased to announce its participation as a sponsor in Advanced Imaging 2023: Pericardial Disease, a prestigious joint meeting sponsored by the British Society of Echocardiography and the Royal Society of Medicine. The event is scheduled to take place in London, England on July 18, 2023. The conference promises a comprehensive overview of multimodality imaging and intervention for pericardial disease. Ventripoint’s VMS+ solution provides physicians with real-time volume data to monitor the treatment and progression of pericardial disease.
This is Ventripoint’s inaugural attendance at this conference as partner of the British Society of Echocardiography. The company is thrilled to be part of this esteemed gathering alongside Ventripoint’s distribution partner, Cardiologic. Ventripoint looks forward to joining the conversation and showcasing our products alongside other cutting-edge solutions in cardiac imaging and intervention for cardiac disease. We endeavor to partner with world class physicians and hospitals alike to provide innovative diagnostic and treatment solutions that elevate cardiac care by improving the patient experience.
Advanced Imaging 2023 serves as a unique platform where leading professionals, researchers, and healthcare practitioners can collaborate and exchange knowledge, advancements, and best practices in the field of multimodality imaging and intervention for pericardial disease. It is very important for pericardial disease to be detected and managed with precise imaging in order to provide effective treatment. With the overarching goal of advancing patient care and cardiovascular health for pericardial disease, the conference offers a diverse program of lectures and interactive case discussions.
Ventripoint’s VMS+ family of products enable precise and accurate volumetric analysis of the heart, providing insights for clinicians in diagnosing and monitoring cardiovascular diseases.
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint’s VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint’s products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe, and Canada.
For further information, please contact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.
Forward Looking Statements
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.
Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management’s discussion and analysis that is available on the Company’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.
Copyright (c) 2023 TheNewswire – All rights reserved.
